152 related articles for article (PubMed ID: 37583001)
1. Loss of SATB2 and CDX2 expression is associated with DNA mismatch repair protein deficiency and BRAF mutation in colorectal cancer.
Li J; Zeng Q; Lin J; Huang H; Chen L
Med Mol Morphol; 2024 Mar; 57(1):1-10. PubMed ID: 37583001
[TBL] [Abstract][Full Text] [Related]
2. SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer.
Ma C; Olevian D; Miller C; Herbst C; Jayachandran P; Kozak MM; Chang DT; Pai RK
Mod Pathol; 2019 Jul; 32(8):1217-1231. PubMed ID: 30962505
[TBL] [Abstract][Full Text] [Related]
3. Loss of SATB2 Expression in Colorectal Carcinoma Is Associated With DNA Mismatch Repair Protein Deficiency and BRAF Mutation.
Ma C; Olevian DC; Lowenthal BM; Jayachandran P; Kozak MM; Chang DT; Pai RK
Am J Surg Pathol; 2018 Oct; 42(10):1409-1417. PubMed ID: 30001238
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive clinicopathologic, molecular, and immunologic characterization of colorectal carcinomas with loss of three intestinal markers, CDX2, SATB2, and KRT20.
Lee JA; Seo MK; Yoo SY; Cho NY; Kwak Y; Lee K; Kim JH; Kang GH
Virchows Arch; 2022 Mar; 480(3):543-555. PubMed ID: 35029777
[TBL] [Abstract][Full Text] [Related]
5. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.
Neumann J; Heinemann V; Engel J; Kirchner T; Stintzing S
Virchows Arch; 2018 Aug; 473(2):199-207. PubMed ID: 29675807
[TBL] [Abstract][Full Text] [Related]
6. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
[TBL] [Abstract][Full Text] [Related]
7. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
[TBL] [Abstract][Full Text] [Related]
8. Concomitant expression patterns of CDX2 and SATB2 as prognostic factors in stage III colorectal cancers.
Lee JA; Park HE; Jin HY; Jin L; Cho NY; Bae JM; Kim JH; Kang GH
Ann Diagn Pathol; 2024 Aug; 71():152289. PubMed ID: 38555678
[TBL] [Abstract][Full Text] [Related]
9. The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma.
Skalova A; Sar A; Laco J; Metelkova A; Miesbauerova M; Steiner P; Švajdler M; Michal M
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):140-146. PubMed ID: 27258560
[TBL] [Abstract][Full Text] [Related]
10. Molecular Deciphering of Colorectal Cancer: Exploring Molecular Classifications and Analyzing the Interplay among Molecular Biomarkers MMR/MSI, KRAS, NRAS, BRAF and CDX2 - A Comprehensive Literature Review.
Ilie-Petrov AC; Cristian DA; Diaconescu AS; Chitul A; Blajin A; Popa A; Mandi DM; Negreanu R; Vieru C; Vrîncianu R; Ardeleanu CM
Chirurgia (Bucur); 2024 Apr; 119(2):136-155. PubMed ID: 38743828
[No Abstract] [Full Text] [Related]
11. The Prognostic Utilities of DNA Mismatch Repair Status and KRAS and BRAF Mutation in Korean Colorectal Cancer Patients: The KASID Multicenter Study.
Kim TW; Hwang SW; Kim KO; Cha JM; Joo YE; Cho YS
Oncology; 2023; 101(1):49-58. PubMed ID: 36191562
[TBL] [Abstract][Full Text] [Related]
12. BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer.
Tan E; Whiting J; Xie H; Imanirad I; Carballido E; Felder S; Frakes J; Mo Q; Walko C; Permuth JB; Sommerer K; Kim R; Anaya DA; Fleming JB; Sahin IH
Oncologist; 2022 Mar; 27(3):191-197. PubMed ID: 35274712
[TBL] [Abstract][Full Text] [Related]
13. Loss of CDX-2 expression is an independent poor prognostic biomarker in patients with early-stage deficient mismatch repair colorectal cancer.
Korphaisarn K; Sukhokanjanachusak K; Pongpaibul A; Chinswangwatanakul V; Akewanlop C
Asia Pac J Clin Oncol; 2022 Jun; 18(3):249-258. PubMed ID: 34161647
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single-center retrospective study of 1,834 Chinese patients with Stage I-IV colorectal cancer.
Guo TA; Wu YC; Tan C; Jin YT; Sheng WQ; Cai SJ; Liu FQ; Xu Y
Int J Cancer; 2019 Sep; 145(6):1625-1634. PubMed ID: 31162857
[TBL] [Abstract][Full Text] [Related]
15. Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study.
Mezheyeuski A; Ponten F; Edqvist PH; Sundström M; Thunberg U; Qvortrup C; Pfeiffer P; Sorbye H; Glimelius B; Dragomir A
Acta Oncol; 2020 Mar; 59(3):284-290. PubMed ID: 31769323
[No Abstract] [Full Text] [Related]
16. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.
Ta TV; Nguyen QN; Chu HH; Truong VL; Vuong LD
Pathol Res Pract; 2020 Apr; 216(4):152898. PubMed ID: 32089414
[TBL] [Abstract][Full Text] [Related]
17. Relationship between mismatch repair protein,
Fan JZ; Wang GF; Cheng XB; Dong ZH; Chen X; Deng YJ; Song X
World J Clin Cases; 2021 Apr; 9(11):2458-2468. PubMed ID: 33889611
[TBL] [Abstract][Full Text] [Related]
18. SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary.
Dabir PD; Svanholm H; Christiansen JJ
APMIS; 2018 Jun; 126(6):494-500. PubMed ID: 29924451
[TBL] [Abstract][Full Text] [Related]
19. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS.
Wang J; Yi Y; Xiao Y; Dong L; Liang L; Teng L; Ying JM; Lu T; Liu Y; Guan Y; Pang J; Zhou L; Lu J; Zhang Z; Liu X; Liang X; Zeng X; Yi X; Zhou W; Xia X; Yang L; Zhang J; Kopetz S; Futreal PA; Wu H; Liang Z
Mod Pathol; 2019 Jul; 32(7):1053-1064. PubMed ID: 30723297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
